3:00 p.m. Spotlight Theater B Northwest Biotherapeutics Title: Clinical development of dendritic cell‐based therapies for both resectable and unresectable tumors Abstract: Dr. Bosch will discuss NW Bio’s DCVax® platform technology, a personalized, dendritic cell based active immunotherapy for solid tumors. Unlike conventional cancer drugs and other immune therapies, which use one active agent to hit one target on the cancer, DCVax mobilizes many active agents of the immune system to hit many targets on the cancer. NW Bio’s lead product, DCVax‐L, is designed to treat all types of operable solid tumors. DCVax‐L is currently in a 348‐patient international Phase III clinical trial for patients with newly‐diagnosed Glioblastoma multiforme brain cancer. DCVax‐L has also been applied in a Phase I trial with metastatic ovarian cancer, and in various other types of cancers in compassionate use cases. Dr. Bosch will provide updates on the clinical programs and related special access programs. NW Bio’s second product, DCVax‐Direct, is designed to treat all types of inoperable solid tumors, through intra‐tumoral injection anywhere in the body. DCVax‐Direct is being evaluated in an ongoing 60‐patient Phase I/II trial, in which more than 7 different cancers have been treated to date. Dr. Bosch will provide updates about this program and the technology involved. Speaker: Marnix Bosch
Amazing. This is NWBO first slide on CI. Non exclusive so any company can add DCVAX,,Celgene to PFE.
These were the patients so far gone that they did not even qualify for the trial. These results on this group is just well...amazing !!!!!!
The word is spreading among the educated funds and media.
Do the math and measure all metrics..If you don't know please do not post garbage.
Even better news coming too. Keep adding.
Buying anything below $2.
They were on deaths door.. this is $100 news !!!
Even a Washington Post Pulitzer Prize winner called him out for his outright manipulation and childish antics. Imo company legal team keeping all records, tweets, publications, trading records, short sales and anyone assisting.
More news coming. Then ASCO
Worldwide and accelerating. Each week more big money learns and buys.
Medytox Solutions reported revenues of $21.1 million and $52.5 million for 2012 and 2013, respectively. Medytox Solutions reported net income attributable to common stockholders of $2.3 million and $5.7 million for 2012 and 2013, respectively. Medytox Solutions reported revenues (gross charges, net of contractual allowances and discounts), net revenues and net income attributable to common stockholders of $64.7 million, $49.0 million and $7.7 million, respectively, for the nine months ended September 30, 2014. As of September 30, 2014, Medytox Solutions reported $24.2 million of current assets and $38.2 million of total assets.
What he meant is that he said nothing negative when asked his thoughts on NWBO. I expected a negative answer to support AF. He did no such thing. I think Jim will eventually talk well of NWBO but at that time it will be $20+